Elysium Heath also announced Morgan Levine, Ph.D., of Yale School of Medicine has joined the company as head of bioinformatics to improve the testing methodology of Index, with the goal of making its application accurate and informative for individuals.
Cepheid announced that it has received clearance from the FDA for its Xpert BCR-ABL Ultra for monitoring disease burden in patients with chronic myeloid...
A study of the tongue microbiome reveals some types of bacteria can distinguish people with early pancreatic cancer from healthy individuals
Company will leverage synthetic biology and CRISPR patents held by the Broad Institute and Harvard's Wyss Institute to create next-gen MDxes
According to Myriad, it is the first and only genetic test approved by the FDA as a CDx designed to help identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with Lynparza.
MammaPrint and BluePrint reclassified 40% of pathologically subtyped tumors, highlighting the need for an individualized, molecular subtyping profile in early stage breast cancer diagnosing for patients.
Bringing it closer to one of the world’s fastest-growing diagnostic market places, the Laboratory for Advanced Medicine (LAM)’s blood-based liver cancer test has been...
Led by UCL researchers, the team identified a heritability estimate for Lewy Body Dementia of 36%, similar to that of Parkinson's disease
Company plans to launch STRATAFIDE multi-gene, pan-solid tumor companion diagnostic, designed to identify actionable genomic alterations in tissue or blood, and support development of its Personalized Cancer Monitoring (PCM) platform.
The overall specificity of the methylation-based cfDNA test was 99.3%; meaning that less than 1% of those without cancer were wrongly identified by the system as having the disease.